These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25683946)

  • 21. Beta-blockers for hypertension.
    Wiysonge CS; Bradley H; Mayosi BM; Maroney R; Mbewu A; Opie LH; Volmink J
    Cochrane Database Syst Rev; 2007 Jan; (1):CD002003. PubMed ID: 17253471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood-Letting Therapy for Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Xiong XJ; Wang PQ; Li SJ
    Chin J Integr Med; 2019 Feb; 25(2):139-146. PubMed ID: 29959751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Garlic for hypertension: A systematic review and meta-analysis of randomized controlled trials.
    Xiong XJ; Wang PQ; Li SJ; Li XK; Zhang YQ; Wang J
    Phytomedicine; 2015 Mar; 22(3):352-61. PubMed ID: 25837272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
    J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Safety and Efficacy of Quadruple Ultra-Low-Dose Combination (Quadpill) for Hypertension Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Abuelazm M; Ali S; Saleh O; Badr A; Altobaishat O; AlBarakat MM; Aboutaleb A; Siddiq A; Abdelazeem B
    Clin Drug Investig; 2023 Nov; 43(11):813-826. PubMed ID: 37902939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension: a meta-analysis.
    Zhao D; Liu H; Dong P
    Ir J Med Sci; 2019 May; 188(2):481-488. PubMed ID: 29971568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.
    Zou Z; Xi GL; Yuan HB; Zhu QF; Shi XY
    J Hum Hypertens; 2009 May; 23(5):339-49. PubMed ID: 18987649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldosterone Synthase Structure With Cushing Disease Drug LCI699 Highlights Avenues for Selective CYP11B Drug Design.
    Brixius-Anderko S; Scott EE
    Hypertension; 2021 Sep; 78(3):751-759. PubMed ID: 34247511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    McGill JB; Reilly PA
    Clin Ther; 2001 Jun; 23(6):833-50. PubMed ID: 11440284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial.
    Sohn IS; Kim CJ; Oh BH; Hong TJ; Park CG; Kim BS; Chung WB;
    Am J Cardiovasc Drugs; 2016 Apr; 16(2):129-38. PubMed ID: 26691333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study.
    Oh GC; Han JK; Han KH; Hyon MS; Doh JH; Kim MH; Jeong JO; Bae JH; Kim SH; Yoo BS; Baek SH; Rhee MY; Ihm SH; Sung JH; Choi YJ; Kim SJ; Hong KS; Lee BK; Cho J; Shin ES; Rhew JY; Kim H; Kim HS
    Clin Ther; 2018 May; 40(5):676-691.e1. PubMed ID: 29673890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension.
    Kang S; Wu YF; An N; Ren M
    Clin Ther; 2004 Feb; 26(2):257-70. PubMed ID: 15038948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.
    Ball KJ; Williams PA; Stumpe KO
    J Hypertens Suppl; 2001 Jun; 19(1):S49-56. PubMed ID: 11451215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
    Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
    Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy.
    Tuomilehto J; Tykarski A; Baumgart P; Reimund B; Le Breton S; Ferber P
    Blood Press Suppl; 2008 Jun; 1():15-23. PubMed ID: 18705531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials.
    Weiss RJ; Saunders E; Greathouse M
    Clin Ther; 2011 Sep; 33(9):1150-61. PubMed ID: 21864908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
    Chua SK; Lai WT; Chen LC; Hung HF
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34206864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
    Stumpe KO
    Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.